Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ascendis Pharma ( (ASND) ) just unveiled an update.
On January 8, 2026, Ascendis Pharma reported positive Week 52 topline data from its Phase 2 COACH trial, the first study to evaluate once-weekly combination therapy with TransCon CNP and TransCon hGH in children aged 2 to 11 years with achondroplasia, showing durable increases in growth velocity, improved body proportionality and arm span, and no new safety concerns compared with the individual monotherapies. The results, which included annualized growth velocities above the 97th percentile of average-stature children and maintenance of bone age in line with chronological age, support Ascendis’s strategy to advance a Phase 3 program in pediatric achondroplasia and could strengthen the company’s position in the rare endocrine and skeletal dysplasia market as TransCon CNP undergoes priority regulatory review in the U.S. and Europe and all enrolled children continue on treatment in the COACH trial.
The most recent analyst rating on (ASND) stock is a Buy with a $242.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
Spark’s Take on ASND Stock
According to Spark, TipRanks’ AI Analyst, ASND is a Neutral.
Ascendis Pharma’s overall stock score is primarily influenced by its financial performance challenges, including high leverage and negative cash flows. While the earnings call provided positive insights into revenue growth and regulatory progress, the stock’s valuation remains unattractive due to ongoing losses. Technical indicators suggest a lack of strong momentum, further impacting the score.
To see Spark’s full report on ASND stock, click here.
More about Ascendis Pharma
Ascendis Pharma A/S is a Denmark-based biopharmaceutical company focused on developing and commercializing long-acting therapies for rare endocrine diseases and related conditions. Its pipeline includes TransCon CNP, an investigational prodrug of C-type natriuretic peptide for children with achondroplasia, and TransCon hGH, a long-acting growth hormone prodrug marketed as SKYTROFA for pediatric and adult growth hormone deficiency, with additional development in achondroplasia and other indications.
Average Trading Volume: 579,218
Technical Sentiment Signal: Buy
Current Market Cap: $13.03B
For a thorough assessment of ASND stock, go to TipRanks’ Stock Analysis page.